ImmuCell Corporation (ICCC)

This article provides a financial overview of Immucell Corp (ICCC), focusing on its revenue breakdown and other key financial data. It includes sections on insider trading, institutional ownership, analyst ratings, and a company profile. The data presented covers various aspects of the company's financial health and market performance.

ImmuCell (NASDAQ:ICCC) reported mixed Q2 2026 results, with product sales up 11.5% to $7.2 million, but gross margin significantly compressed from 43.7% to 33.9%. Despite a tripling of net income to $1.8 million largely due to a $2 million legal settlement, the stock dropped 8.44%. The company is investing $8 million in capacity expansion to address production constraints and improve efficiency.

ImmuCell Corporation (ICCC) is a biotechnology company focused on veterinary products, particularly for enhancing immune health in livestock. The company's stock recently traded at $10.20, down 6.47%, and has a market cap of $78.93 million. Recent news highlights include Q2 2026 earnings results, increased sales, plans to expand manufacturing capacity, and a strategic pivot after the FDA rejected its mastitis treatment.

ImmuCell Corporation reported an 11.5% increase in Q2 2026 product sales, reaching $7.2 million, driven by strong domestic growth but tempered by international sales decline. The company's strategic focus on the calf scours market with its First Defense product has led to accelerated growth and increased market share, particularly in the U.S. Despite a reduced gross margin due to manufacturing output and cost shifts, ImmuCell achieved a net income of $1.8 million, boosted by a $2 million legal settlement, and plans significant investments to triple manufacturing capacity and improve product costs.

IMMUCELL CORP /DE/ (ICCC) reported strong second-quarter 2026 results, with revenue reaching $7.19 million and net income climbing to $1.83 million, significantly up from the previous year. This growth was primarily fueled by increased sales volumes and pricing of its First Defense product. The company also announced plans to expand its First Defense drying and liquid capacity by converting its former Re-Tain facility.